Drug Approval | December 03, 2025
LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Now a test that offers new precision in prostate cancer detection
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
Subscribe To Our Newsletter & Stay Updated
